At a glance
ClinicalIndex Comparison RecordPhase 2Active· 39 target
Drug / intervention
Atezolizumab Injection [Tecentriq] +1 moredrug
Likely dose
Atezolizumab Injection [Tecentriq] 1.200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)
In Brief
A Phase 2 clinical trial evaluating Atezolizumab Injection [Tecentriq] and External Beam Radiation Therapy (EBRT) for Bladder Cancer. Active but no longer recruiting, targeting 39 participants across 10 sites.
Detailed Summary
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality bladder conservative approach.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesSpain
CollaboratorsRoche Farma, S.A, Dynamic Science S.L.
Timeline
Phase 2Active
20202021202220232024202520262027
Enrollment StartSep 2019
First PostedDec 2019
TodayJul 2026
Primary CompletionFeb 2027
Study CompletionMay 2027
First PostedDec 4, 2019
Enrollment StartSep 18, 2019
Primary CompletionFeb 1, 2027
Study CompletionMay 1, 2027
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 6.6 years agoPrimary completion in 7 months
Interventions
Atezolizumab Injection [Tecentriq]drug
intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
External Beam Radiation Therapy (EBRT)radiation
60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day